ELAN Elanco Animal Health (ELAN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001739104
Cluster · 7 insidersC-suite buying · 4Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
248
13F, latest reported quarter
What the filings say about ELAN
Insiders, 180 days
+$1.6M net bought
7 buyers · 1 seller · 100% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-09-23
Planned sales (Form 144), 90 days
$100.0K
1 notice
Elanco Animal Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Elanco Animal Health Inc insiders bought a net $1.6M of stock across 41 Form 4 purchases and sales, with 7 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.1% of the 138,911 shares held after it.
- No other insider sold within 30 days.
- 248 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SEE REMARKS Bettington Timothy J sold about $100.0K of ELAN under a 10b5-1 plan on Oct 15, 2026, the largest insider sale at the company on our record; 248 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 12, 2025.
- +20.6% median (+21.9% mean) 90-day return after 3 previous buys.
- The trade is 21.2% of the 188,647 shares held after it.
- 4 other insiders bought within 30 days.
- 248 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kurzius Lawrence Erik bought about $935.9K of ELAN on Aug 20, 2026, the largest insider purchase at the company since 2024; 4 other insiders bought within 30 days and 248 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.6% of the 87,832 shares held after it.
- 4 other insiders bought within 30 days.
- 248 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GC AND CORP SEC O'Neill Shiv bought about $94.3K of ELAN on Aug 18, 2026; 4 other insiders bought within 30 days and 248 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 22, 2024.
- +5.0% median (+3.8% mean) 90-day return after 4 previous buys.
- The trade is 3.8% of the 131,451 shares held after it.
- 4 other insiders bought within 30 days.
- 248 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Harrington Michael J bought about $109.1K of ELAN on Aug 12, 2026; 4 other insiders bought within 30 days and 248 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 9, 2022.
- The trade is 9.0% of the 111,687 shares held after it.
- 4 other insiders bought within 30 days.
- 248 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Herendeen Paul bought about $236.8K of ELAN on Aug 7, 2026; 4 other insiders bought within 30 days and 248 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.6M over 180 days
+$1.4M over 90 days
more than 91% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
248 funds bought in last quarter
more than 93% of Pharma & Biotech
Revenue
+6.2% year over year
more than 55% of Pharma & Biotech
Margin
-4.9% net margin
more than 69% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.5% of the float short (float per yahoo 2026-10-26) · 6.2 days to cover · settled 2026-09-30
more than 62% of Pharma & Biotech
The situation: each line is one rule over one dataset
7 insiders bought a net $1.6M, but 1 Form 144 notice ($100.0K) are queued to sell.
What changed in the last 30 days
Oct 19SEE REMARKS Bettington Timothy J sold $100.0K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Officer Bettington Timothy J filed to sell $100.0K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ELAN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.5%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ELAN: institutional holders (13F)
13F holdings, latest reported quarter
67,397,025 sh
$1.7B
56,948,819 sh
$1.4B
48,849,973 sh
$1.2B
45,445,012 sh
$1.1B
25,417,271 sh
$625.5M
Congress trades in ELAN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-09-23 · disclosed 17 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ELAN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Bettington Timothy J
Filed 2026-10-15
$100.0K
ELAN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Pharmaceuticals Portfolio
$62.3M position · as of 2026-05-31
4.1%
Fundamental Large Cap Value Trust
$30.8M position · as of 2026-06-30
3.7%
Timothy Plan Small/Mid Cap Growth Fund
$5.3M position · as of 2026-06-30
3.0%
iShares U.S. Pharmaceuticals ETF
$31.9M position · as of 2026-06-30
2.8%
Brandes U.S. Small-Mid Cap Value ETF
$4.4M position · as of 2026-06-30
2.7%
Fundamental All Cap Core Trust
$53.6M position · as of 2026-06-30
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Jeffrey Simmons
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.9M
$37.8M
$3.8M
-26%
+88%
2024
$14.8M
$9.2M
$3.4M
-61%
+48%
2023
$13.7M
$17.3M
$3.0M
-51%
+37%
2022
$12.7M
-$2.0M
$2.8M
-60%
+36%
2021
$12.1M
$16.5M
$3.2M
-7%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
7 insiders reported buying shares.
The record shows a net $1.6M bought by insiders over 180 days, 248 funds added last quarter, $100.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ELAN financials
Revenue growth
+6.2%
XBRL, annual
Net margin
-4.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ELAN
| FY Dec 2025 | $4.7B |
| FY Dec 2024 | $4.4B |
| FY Dec 2023 | $4.4B |
| FY Dec 2022 | $4.4B |
| FY Dec 2021 | $4.8B |
| Jun 2026 | $1.4B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.1B |
| Sep 2025 | $1.1B |
| Jun 2025 | $1.2B |
| Mar 2025 | $1.2B |
| Dec 2024 | $1.0B |
| Sep 2024 | $1.0B |
At each fiscal year end
Single quarter
Net margin, TTM
-4.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ELAN
| FY Dec 2025 | -4.9% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | -27.9% |
| FY Dec 2022 | -1.8% |
| FY Dec 2021 | -10.1% |
| Jun 2026 | +3.9% |
| Mar 2026 | +4.2% |
| Dec 2025 | -24.1% |
| Sep 2025 | -3.0% |
| Jun 2025 | +0.9% |
| Mar 2025 | +5.6% |
| Dec 2024 | -0.8% |
| Sep 2024 | +35.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$379.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ELAN
| FY Dec 2025 | $284.0M |
| FY Dec 2024 | $394.0M |
| FY Dec 2023 | $131.0M |
| FY Dec 2022 | $281.0M |
| FY Dec 2021 | $324.0M |
| Jun 2026 | $244.0M |
| Mar 2026 | -$38.0M |
| Dec 2025 | $46.0M |
| Sep 2025 | $127.0M |
| Jun 2025 | $180.0M |
| Mar 2025 | -$69.0M |
| Dec 2024 | $130.0M |
| Sep 2024 | $120.0M |
At each fiscal year end
Single quarter
Debt to equity
0.56x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity ELAN
| FY Dec 2025 | 0.57x |
| FY Dec 2024 | 0.71x |
| FY Dec 2023 | 0.93x |
| FY Dec 2022 | 0.80x |
| FY Dec 2021 | 0.84x |
| Jun 2026 | 0.56x |
| Mar 2026 | 0.57x |
| Dec 2025 | 0.57x |
| Sep 2025 | 0.56x |
| Jun 2025 | 0.58x |
| Mar 2025 | 0.69x |
| Dec 2024 | 0.71x |
| Sep 2024 | 0.67x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.17x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt ELAN
| FY Dec 2025 | 0.15x |
| FY Dec 2024 | 0.13x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | 0.08x |
| FY Dec 2021 | 0.08x |
| Jun 2026 | 0.17x |
| Mar 2026 | 0.15x |
| Dec 2025 | 0.15x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.14x |
| Mar 2025 | 0.12x |
| Dec 2024 | 0.13x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-3.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ELAN
| FY Dec 2025 | -3.7% |
| FY Dec 2024 | +5.5% |
| FY Dec 2023 | -18.2% |
| FY Dec 2022 | -1.1% |
| FY Dec 2021 | -6.1% |
| Jun 2026 | -3.0% |
| Mar 2026 | -3.8% |
| Dec 2025 | -3.7% |
| Sep 2025 | +0.5% |
| Jun 2025 | +6.8% |
| Mar 2025 | +6.0% |
| Dec 2024 | +5.5% |
| Sep 2024 | +3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ELAN
| FY Dec 2025 | -1.8% |
| FY Dec 2024 | +2.5% |
| FY Dec 2023 | -8.2% |
| FY Dec 2022 | -0.5% |
| FY Dec 2021 | -2.8% |
| Jun 2026 | -1.5% |
| Mar 2026 | -1.8% |
| Dec 2025 | -1.8% |
| Sep 2025 | +0.3% |
| Jun 2025 | +3.2% |
| Mar 2025 | +2.8% |
| Dec 2024 | +2.5% |
| Sep 2024 | +1.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital ELAN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed ELAN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ELAN
| FY Dec 2025 | n/a |
| FY Dec 2024 | 18.07x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 335.67x |
| Jun 2025 | 16.60x |
| Mar 2025 | 14.19x |
| Dec 2024 | 18.07x |
| Sep 2024 | 36.72x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$14.6B
market value at close 2026-10-26 on 2026-08-03 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value ELAN
| FY Dec 2025 | $14.5B |
| FY Dec 2024 | $9.8B |
| FY Dec 2023 | $12.8B |
| FY Dec 2022 | $11.3B |
| FY Dec 2021 | $19.1B |
| Jun 2026 | $15.4B |
| Mar 2026 | $15.2B |
| Dec 2025 | $14.5B |
| Sep 2025 | $13.3B |
| Jun 2025 | $10.5B |
| Mar 2025 | $9.1B |
| Dec 2024 | $9.8B |
| Sep 2024 | $11.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield ELAN
| FY Dec 2025 | +2.5% |
| FY Dec 2024 | +6.6% |
| FY Dec 2023 | +1.8% |
| FY Dec 2022 | +4.8% |
| FY Dec 2021 | +2.4% |
| Jun 2026 | +3.1% |
| Mar 2026 | +2.6% |
| Dec 2025 | +2.5% |
| Sep 2025 | +3.7% |
| Jun 2025 | +5.1% |
| Mar 2025 | +6.7% |
| Dec 2024 | +6.6% |
| Sep 2024 | +5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ELAN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.7B | $4.4B | $4.4B | $4.4B |
| Gross profit | $2.6B | $2.4B | $2.5B | n/a |
| Net income | -$232.0M | $338.0M | -$1.2B | -$78.0M |
| EPS (diluted) | -0.47 | 0.68 | -2.50 | -0.16 |
| Operating cash flow | $560.0M | $541.0M | $271.0M | $452.0M |
| Cash | $545.0M | $468.0M | $352.0M | $345.0M |
| Long-term debt | $3.8B | $4.3B | $5.7B | $5.4B |
SEC XBRL, fiscal years, as known on 2026-10-28
ELAN Stock Sonar score 6/7 axes
Find similar shapesCompareELAN ranks highest on insider conviction (95th percentile) and institutional and government (86th), and lowest on risk and compliance (33rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ELAN filings, in plain words
Are Elanco Animal Health insiders buying or selling ELAN?
In the 180 days to 2026-10-28, Elanco Animal Health insiders were net buyers, a net $1.6M: $1.7M of purchases and $100.0K of sales reported on Form 4, by 7 buyers and 1 seller.
Have members of Congress traded ELAN?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Valerie Hoyle dated 2025-09-23.
Are there planned insider sales of ELAN?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $100.0K of stock; the latest, by Bettington Timothy J, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-28, Elanco Animal Health insiders were net buyers of ELAN, a net $1.6M across purchases and sales reported on Form 4 by 7 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 5 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Members of Congress have disclosed trades in ELAN, none in the last year; the latest on record is a sale by Valerie Hoyle dated 2025-09-23. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $100.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
